Lilly acquires Ajax Therapeutics

Eli Lilly has announced the acquisition of Ajax Therapeutics for up to $2.3 billion, aiming to bolster its oncology pipeline. The deal highlights Lilly's strategic focus on expanding its portfolio of cancer treatments, specifically targeting myeloproliferative neoplasms (MPNs), which are rare blood disorders characterized by the overproduction of blood cells.

The acquisition includes an upfront payment and potential future payments tied to clinical and regulatory milestones. While the specific financial breakdown has not been disclosed, the acquisition underscores Lilly's interest in Ajax's lead candidate, AJ1-11095. This oral Type II JAK2 inhibitor is currently in Phase I trials for myelofibrosis—a form of MPN—for patients previously treated with Type I JAK2 inhibitors. Ajax claims AJ1-11095 may offer greater efficacy and disease modification than existing treatments.

Lilly’s executive vice president and president of Lilly Oncology, Jacob Van Naarden, emphasized the potential of AJ1-11095 to deliver deeper efficacy and a favorable tolerability profile, which could allow for broader clinical use. This acquisition aligns with Lilly's history with Ajax, having been a strategic investor in Ajax's Series C financing round in 2024. CEO of Ajax, Martin Vogelbaum, expressed optimism about Lilly advancing the development of AJ1-11095 to provide a new therapeutic option for MPN patients.

The acquisition is part of Lilly’s ongoing strategy to strengthen its presence in oncology through mergers and acquisitions, having completed six deals in 2026 alone. This includes other oncology-focused acquisitions, reflecting a broader industry trend as companies prepare for an impending patent cliff by diversifying and enhancing their drug pipelines. Competitors like GSK have also pursued similar M&A strategies, underscoring the competitive landscape in oncology drug development.

With established JAK inhibitors such as Incyte's Jakafi and Bristol Myers Squibb's Inrebic leading the market, Lilly’s addition of AJ1-11095 signals a focused attempt to offer alternative treatment options. Market observers will be keen to see how the acquisition impacts the competitive dynamics in the MPN therapeutics space and the potential regulatory milestones necessary to successfully integrate Ajax into Lilly’s operations. As the deal moves forward, achieving the clinical and regulatory benchmarks will be pivotal for realizing the acquisition’s full value.